PostCOVID effect on endothelial function in hypertensive patients: A new research opportunity

SARS‐CoV‐2 is causing devastation both in human lives and economic resources. When the world seems to start overcoming the pandemics scourge, the threat of long‐term complications of COVID‐19 is rising. Reports show that some of these long‐term effects may contribute to the main cause of morbimortal...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of Clinical Hypertension 2022-02, Vol.24 (2), p.200-203
Main Authors: Giménez‐Miranda, Luis, Beltrán‐Romero, Luis, León‐Jimenez, David, Stiefel, Pablo
Format: Article
Language:English
Subjects:
Atherosclerosis
Cancer
Cardiovascular disease
circulating free DNA
Conflicts of interest
Coronary vessels
COVID-19
Endothelial Cells
endothelial dysfunction
endothelial microparticles
Endothelium, Vascular
Humans
Hypertension
Hypertension - epidemiology
Ischemia
Laser‐Doppler flowmetry
Metastasis
Mitochondrial DNA
Opinion
Patients
Preeclampsia
Risk factors
SARS CoV‐2
Severe acute respiratory syndrome coronavirus 2
Sleep apnea
Vasodilation
Vein & artery diseases
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:SARS‐CoV‐2 is causing devastation both in human lives and economic resources. When the world seems to start overcoming the pandemics scourge, the threat of long‐term complications of COVID‐19 is rising. Reports show that some of these long‐term effects may contribute to the main cause of morbimortality worldwide: the vascular diseases. Given the evidence of damage in the endothelial cells due to SARS‐CoV‐2 and that endothelial dysfunction precedes the development of arteriosclerosis, the authors propose to measure endothelial function around 6–12 months after acute disease in hypertensive patients, especially if they have other cardiovascular risk factors or overt vascular disease. The methods the authors propose are cost‐effective and can be made available to any hypertension unit. These methods could be the “in vivo” assessment of endothelial function by flow mediated vasodilatation after ischemia by Laser‐Doppler flowmetry and the measurement of plasma free circulating DNA and microparticles of endothelial origin.
ISSN:1524-6175
1751-7176
DOI:10.1111/jch.14376